title: Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia.
abstract: OBJECTIVE
  The objectives of this 12-week multicenter, open-label, noncomparative study were to evaluate the overall effectiveness of paliperidone extended release (ER), the feasibility of maintaining patients on the initial dose of 6 mg, and the relationship between dose pattern and treatment response in schizophrenic patients with inadequate responses to initial treatment in a natural setting.
  
  
  METHODS
  All patients received 6 mg of paliperidone ER during the first 2 weeks, and subsequently, the dose was adjusted at each visit based on the patient response. We examined the response rate and the effectiveness of different dose patterns of paliperidone ER such as "early increase (dose increased to 9 mg at week 2)," "late increase (dose increased to 9 mg at week 4)," and "maintenance group."
  
  
  RESULTS
  The response rate based on the Clinical Global Impression of Improvement or Severity response criteria was 33.6% or 61.7%, respectively. The proportion of patients who stayed with the initial dose of 6 mg was 44.5% and the response rate of these patients was 79.8%. When the treatment response to the initial dose of 6 mg is inadequate (Clinical Global Impression of Improvement ≥ 4 at week 2), an early increase in the dose seems to be more effective than maintenance or late increase of the initial dose.
  
  
  CONCLUSIONS
  This study suggests that paliperidone ER may be an effective and well-tolerated antipsychotics in the treatment of patients with schizophrenia.
authors: Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors: Jung-Sun
authors: JS
authors: Lee
authors: Joon-Ho
authors: JH
authors: Ahn
authors: Jong-Il
authors: JI
authors: Lee
authors: Jong-Hoon
authors: JH
authors: Kim
authors: InKwa
authors: I
authors: Jung
authors: Chang-Uk
authors: CU
authors: Lee
authors: Jun-Young
authors: JY
authors: Lee
authors: Sang-Ick
authors: SI
authors: Lee
authors: Chang-Yoon
authors: CY
authors: Kim
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D008297:Male; D000068882:Paliperidone Palmitate; D010352:Patient Dropouts / Q000706:statistics & numerical data; D011581:Psychological Tests; D011743:Pyrimidines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013607:Tablets; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D007555:Isoxazoles; D011743:Pyrimidines; D013607:Tablets; D000068882:Paliperidone Palmitate